Valuation: Theracryf Plc

Market Cap 6.07M 5.31M 4.9M 4.51M 8.51M 585M 8.7M 58.56M 23M 286M 22.8M 22.3M 986M P/E 2026 *
-1.42x
P/E 2027 * -1.73x
Enterprise Value 3.92M 3.43M 3.16M 2.91M 5.5M 377M 5.62M 37.81M 14.85M 185M 14.72M 14.4M 636M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.44%
1 week-2.33%
Current month-2.33%
1 month-10.64%
3 months-12.50%
Current year+5.00%
1 week 0.2
Extreme 0.2
0.21
1 month 0.2
Extreme 0.2
0.24
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 30/09/2020
Director of Finance/CFO - 04/09/2023
Chief Tech/Sci/R&D Officer - 30/04/2021
Director TitleAgeSince
Director/Board Member - 13/10/2015
Director/Board Member 64 30/09/2020
Director/Board Member - 31/12/2023
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25 Others

Director

422,727,272 19.8499%
04/03/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
+2.44%-2.33%-17.65%-92.63% 6.07M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.25%-2.60%+34.93%+156.16% 23.36B
Weighted average by Cap. -2.80%-2.36%+40.12%+144.10%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.93M -2.7M -2.49M -4.7M -323M -4.8M -32.32M -12.7M -158M -12.58M -12.31M -544M -3.43M -3M -2.77M -2.55M -4.81M -330M -4.91M -33.08M -12.99M -162M -12.88M -12.6M -557M
Net Debt -2.15M -1.88M -1.74M -1.6M -3.02M -207M -3.08M -20.75M -8.15M -101M -8.08M -7.9M -349M 453K 396K 366K 337K 636K 43.66M 650K 4.37M 1.72M 21.37M 1.7M 1.67M 73.62M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
17/07/26 GBX 0.2100 +2.44% 713,389
16/07/26 GBX 0.2050 0.00% 5,607,382
15/07/26 GBX 0.2050 0.00% 630,552
14/07/26 GBX 0.2050 -4.65% 11,346,230
13/07/26 GBX 0.2150 0.00% 3,333
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002825USD
Average target price
0.0431USD
Spread / Average Target
+1,426.97%

Annual profits - Rate of surprise